Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

Phillip, Moshe; Nimri, Revital; Bergenstal, Richard M; Barnard-Kelly, Katharine; Danne, Thomas; Hovorka, Roman; Kovatchev, Boris P; Messer, Laurel H; Parkin, Christopher G; Ambler-Osborn, Louise; Amiel, Stephanie A; Bally, Lia; Beck, Roy W; Biester, Sarah; Biester, Torben; Blanchette, Julia E; Bosi, Emanuele; Boughton, Charlotte K; Breton, Marc D; Brown, Sue A; Buckingham, Bruce A; Cai, Albert; Carlson, Anders L; Castle, Jessica R; Choudhary, Pratik; Close, Kelly L; Cobelli, Claudio; Criego, Amy B; Davis, Elizabeth; de Beaufort, Carine; de Bock, Martin I; DeSalvo, Daniel J; DeVries, J Hans; Dovc, Klemen; Doyle, Francis J; Ekhlaspour, Laya; Shvalb, Naama Fisch; Forlenza, Gregory P; Gallen, Geraldine; Garg, Satish K; Gershenoff, Dana C; Gonder-Frederick, Linda A; Haidar, Ahmad; Hartnell, Sara; Heinemann, Lutz; Heller, Simon; Hirsch, Irl B; Hood, Korey K; Isaacs, Diana; Klonoff, David C; Kordonouri, Olga; Kowalski, Aaron; Laffel, Lori; Lawton, Julia; Lal, Rayhan A; Leelarathna, Lalantha; Maahs, David M; Murphy, Helen R; Nørgaard, Kirsten; O'Neal, David; Oser, Sean; O’Neal, David; Oser, Tamara; Renard, Eric; Riddell, Michael C; Rodbard, David; Russell, Steven J; Schatz, Desmond A; Shah, Viral N; Sherr, Jennifer L; Simonson, Gregg D; Wadwa, R Paul; Ward, Candice; Weinzimer, Stuart A; Wilmot, Emma G; Battelino, Tadej

doi:10.1210/endrev/bnac022

All Outputs (3)

CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review (2022)
Journal Article
Pemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., …Adolfsson, P. (2023). CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review. Diabetes, Obesity and Metabolism, 25(4), 916-939. https://doi.org/10.1111/dom.14962

The National Institute for Clinical Excellence updated guidance for continuous glucose monitoring (CGM) in 2022, recommending that CGM be available to all people living with type 1 diabetes. Manufacturers can trade in the UK with Conformité Européenn... Read More about CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review.

Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19 (2022)
Journal Article
Khunti, K., Ruan, Y., Davies, J., Field, B. C., Harris, S., Kosiborod, M., …Williams, D. (2022). Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19. Diabetes Care, 45(12), 2838-2843. https://doi.org/10.2337/dc22-0357

OBJECTIVE
To determine the association between prescription of SGLT2 inhibitors (SGLT2is) and diabetic ketoacidosis (DKA) incidence or mortality in people with type 2 diabetes (T2D) hospitalized with COVID-19.

RESEARCH DESIGN AND METHODS
This... Read More about Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19.

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice (2022)
Journal Article
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., …Battelino, T. (2023). Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews, 44(2), 254-280. https://doi.org/10.1210/endrev/bnac022

The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long... Read More about Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.